There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma . Antibody drug conjugates have continued to show activity in urothelial cancer with promising clinical outcomes . Data are also discussed regarding intensification for front-line therapy of metastatic castrate sensitive prostate cancer .